Trial Profile
Phase II study of imatinib mesylate and docetaxel in patients with metastatic or recurrent head and neck squamous cell cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Aug 2012
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Imatinib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 16 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Mar 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.
- 21 Nov 2009 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.